PWM
NKTR icon

Palumbo Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Palumbo Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$720K Buy
10,319
+146
+1% +$10.7K 0.15% 104
2026
Q1 		$732K Sell
10,173
-4,541
-31% -$259K 0.18% 89
2025
Q4 		$622K Sell
14,714
-11,440
-44% -$640K 0.15% 107
2025
Q3 		$1.49M Buy
26,154
+2,382
+10% +$78.8K 0.48% 44
2025
Q2 		$614K Buy
+23,772
New +$267K 0.19% 86

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palumbo Wealth Management's NKTR Position: Q2 2026 in Review

Palumbo Wealth Management increased its Nektar Therapeutics (NKTR) stake by 1.4% in Q2 2026, buying an estimated $10.7K and bringing the position to 10,319 shares worth $720K. The position accounts for 0.15% of the portfolio, ranked #104.

Palumbo Wealth Management first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.49M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Palumbo Wealth Management held 10,319 shares of Nektar Therapeutics worth $720K as of Q2 2026.
  • Palumbo Wealth Management bought 146 Nektar Therapeutics shares in Q2 2026, an estimated $10.7K.
  • Nektar Therapeutics made up 0.15% of Palumbo Wealth Management's portfolio in Q2 2026, its #104 holding.
  • Palumbo Wealth Management first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Palumbo Wealth Management's Nektar Therapeutics position peaked at $1.49M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.